| Abstract P145 – Table 1. Incidence rate of a first CV event in the overall cohort, including all LPs and non‐LPs. | ||||
|---|---|---|---|---|
| CV events (n) | IR per 1000 PY (95% CI) | IRR (95% CI) | aIRR (95%CI)a | |
| Total | 163 | 6.1 (5.3 to 7.1) | ||
| Age (time‐updated) (years) | ||||
| <40 | 29 | 2.4 (1.7 to 3.4) | Refa | Refa |
| 40 to 49 | 55 | 6.1 (4.7 to 8.0) | 2.58 (1.64 to 4.04) | 2.11 (1.33 to 3.33) |
| 5 to 59 | 54 | 13.1 (10.0 to 17.1) | 5.49 (3.50 to 8.62) | 3.87 (2.42 to 6.20) |
| ≥60 | 25 | 19.1 (12.9 to 28.3) | 8.04 (4.71 to 13.72) | 4.56 (2.53 to 8.20) |
| HIV transmission mode | ||||
| MSM | 57 | 3.6 (2.8 to 4.7) | Refa | Refa |
| Heterosexual men | 47 | 12.5 (9.4 to 16.6) | 3.48 (2.37 to 5.12) | 2.43 (1.62 to 3.67) |
| Women | 16 | 4.7 (2.9 to 7.7) | 1.32 (0.76 to 2.30) | 1.14 (0.65 to 1.99) |
| IDU | 28 | 13.7 (9.5 to 19.9) | 3.82 (2.43 to 6.01) | 2.23 (1.35 to 3.71) |
| Unknown/other | 15 | 9.9 (5.9 to 16.4) | 2.75 (1.56 to 4.85) | 1.98 (1.11 to 3.55) |
| CD4 cell count at ART initiation | ||||
| Late presenters, CD4 <200 cells/μL | 63 | 8.7 (6.8 to 11.2) | 1.71 (1.19 to 2.44) | 0.92 (0.62 to 1.36) |
| Late presenters, CD4 200 to ≤350 cells/μL | 42 | 5.3 (3.9 to 7.1) | 1.03 (0.69 to 1.53) | 0.84 (0.56 to 1.26) |
| Non‐late presenters, CD4 >350 cells/μL | 58 | 5.1 (3.9 to 6.6) | Refa | Refa |
| Calendar time (time‐updated) | ||||
| 2005 to 2009 | 8 | 4.5 (2.2 to 9.0) | 0.72 (0.35 to 1.48) | 0.81 (0.39 to 1.69) |
| 2010 to 2014 | 47 | 6.3 (4.8 to 8.4) | 1.02 (0.72 to 1.44) | 1.16 (0.82 to 1.64) |
| 2015 to 2021 | 108 | 6.2 (5.1 to 7.5) | Refa | Refa |
| AIDS‐defining event at ART initiation | ||||
| Yes | 29 | 13.8 (9.6 to 19.9) | 2.52 (1.69 to 3.77) | 1.49 (0.95 to 2.34) |
| No | 134 | 5.5 (4.6 to 6.5) | Refa | Refa |
| Comorbidities at baseline | ||||
| Diabetes | 6 | 32.0 (14.4 to 71.3) | 5.38 (2.38 to 12.17) | 1.32 (0.51 to 3.39) |
| Arterial hypertension | 16 | 14.3 (8.8 to 23.3) | 2.48 (1.48 to 4.15) | 1.83 (1.07 to 3.11) |
| Dyslipidaemia | 13 | 16.5 (9.6 to 28.5) | 2.84 (1.61 to 5.01) | 1.34 (0.71 to 2.55) |
| Chronic kidney disease | 3 | 31.0 (10.0 to 96.1) | 5.13 (1.64 to 16.08) | 1.98 (0.58 to 6.76) |
| Chronic lung disease | 6 | 26.5 (11.9 to 59.0) | 4.45 (1.97 to 10.06) | 1.67 (0.71 to 3.90) |
| Chronic liver disease | 25 | 20.3 (13.7 to 30.1) | 3.74 (2.44 to 5.72) | 2.38 (1.48 to 3.82) |
| Malignancy | 11 | 22.4 (12.4 to 40.5) | 3.85 (2.09 to 7.10) | 2.27 (1.20 to 4.30) |
| Depression | 14 | 9.9 (5.9 to 16.8) | 1.68 (0.97 to 2.90) | 1.08 (0.61 to 1.91) |
aIRR, adjusted incidence rate ratio; CVD, cardiovascular disease (includes ischaemic heart disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease); IDU, injection drug use; IR, incidence rate; IRR, incidence rate ratio.
aAdjusted for age, transmission mode, CD4 cell count at ART initiation, calendar time, AIDS‐defining event at ART initiation and comorbidities (diabetes mellitus type 2, arterial hypertension, dyslipidaemia, chronic kidney, lung, or liver disease, malignancy or depression).